Tag Archives: ALNY

Top 5 Biotech Stocks To Watch Right Now

Monday was a good start to the week for stocks, with major benchmarks climbing around half a percent on the day. Most market participants pointed to a lack of bad news over the weekend and anticipation about expected favorable economic data in the coming days as drivers of the generally positive attitude among investors.

But there are still plenty of factors that are preventing stocks overall from mounting stronger gains, including nervousness about geopolitical issues as well as weaker parts of the global economy. Nevertheless, some stocks posted strong gains, and Puma Biotechnology (NASDAQ:PBYI), Applied Optoelectronics (NASDAQ:AAOI), and Ferroglobe (NASDAQ:GSM) were among the best performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so well.

Image source: Getty Images.

Top 5 Biotech Stocks To Watch Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Shane Hupp]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by equities research analysts at Morgan Stanley from $107.00 to $99.00 in a report released on Friday. The firm presently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price objective would indicate a potential upside of 3.97% from the stock’s current price.

  • [By Joseph Griffin]

    BidaskClub lowered shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a strong-buy rating to a buy rating in a research report released on Monday.

  • [By Keith Speights]

    It’s not exactly David vs. Goliath. However, Bellicum Pharmaceuticals (NASDAQ:BLCM) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are definitely in different leagues right now. Both are clinical-stage biotechs, but Bellicum’s market cap is less than $350 million while Alnylam’s market cap is close to $10 billion.

  • [By Keith Speights]

    Speaking of competition, Ionis should have its hands full battling rivals for Tegsedi assuming the drug wins approval. Alnylam (NASDAQ:ALNY) anticipates winning FDA approval for its hATTR drug patisiran within a few weeks. Because the FDA delayed its decision on Tegsedi, Alnylam appears to be in position to reach the market first. In addition to its first-mover advantage, patisiranappears to have an edge over Tegsedi in efficacy and safety based on clinical data for the two drugs.

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) released first-quarter results last week, but all eyes were looking forward as the company waits for a potential approval of its hereditary TTR amyloidosis (ATTR) drug, patisiran.

Top 5 Biotech Stocks To Watch Right Now: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Ethan Ryder]

    ArQule, Inc. (NASDAQ:ARQL) insider Value Fund L. P. Biotechnology sold 1,035,939 shares of the business’s stock in a transaction dated Wednesday, May 30th. The shares were sold at an average price of $5.00, for a total value of $5,179,695.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

  • [By Stephan Byrd]

    ArQule, Inc. (NASDAQ:ARQL) Director Ronald M. Lindsay acquired 23,900 shares of the company’s stock in a transaction on Thursday, May 10th. The stock was acquired at an average price of $2.67 per share, for a total transaction of $63,813.00. Following the purchase, the director now directly owns 43,900 shares of the company’s stock, valued at $117,213. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

  • [By Joseph Griffin]

    Shares of ArQule, Inc. (NASDAQ:ARQL) were down 5.4% during trading on Wednesday . The company traded as low as $4.71 and last traded at $4.73. Approximately 3,358,864 shares traded hands during trading, an increase of 289% from the average daily volume of 863,008 shares. The stock had previously closed at $5.00.

  • [By Joseph Griffin]

    ValuEngine upgraded shares of ArQule (NASDAQ:ARQL) from a buy rating to a strong-buy rating in a research report released on Tuesday.

    Several other equities analysts have also issued reports on ARQL. Zacks Investment Research upgraded ArQule from a hold rating to a buy rating and set a $2.50 price objective for the company in a research report on Tuesday, March 20th. BidaskClub upgraded ArQule from a buy rating to a strong-buy rating in a research report on Saturday, March 24th. B. Riley set a $4.00 price objective on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Finally, Roth Capital boosted their price objective on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $5.35.

Top 5 Biotech Stocks To Watch Right Now: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Sean Williams, Chuck Saletta, and Brian Feroldi]

    As noted, the ability to take numerous swings for the fence makes Ionis special. It’s often a marvel when a mid-cap drugmaker has a half-dozen experimental drugs, let alone one working with 25. Spinal muscular atrophy drug Spinraza, which was licensed to Biogen (NASDAQ:BIIB), is one such drug that’s put Ionis and its antisense technology on the map. Last year, Spinraza netted “just” $882 million in total sales, but delivered $364 million globally in the first quarter of 2018. That extrapolates out to more than $1.4 billion, which means added royalty revenue for Ionis.

  • [By Brian Feroldi]

    Data source: Alkermes. GAAP = generally accepted accounting principles.

    What happened with Alkermes this quarter?
    Sales of Alkermes’opioid- and alcohol-abuse prevention drug Vivitrol grew 7% to $62.7 million. Sales of the company’sschizophrenia drugAristadarose 62% to $29.2 million. Manufacturing and royalty revenue related toJohnson & Johnson’s schizophrenia drugs jumped 15% to $68.8 million. Manufacturing and royalty revenue related toAcorda Therapeutics’ multiple sclerosis drugfell3% to $28.3 million. Research and development revenue earned as part of its collaboration withBiogen (NASDAQ:BIIB) for BIIB098 — which used to be called ALKS 8700 — was $17.5 million.

    Looking beyond the financials, here’s an overview of the key events from the period:

  • [By ]

    What should investors do with shares of Celgene (CELG) , Biogen Idec (BIIB) , Gilead Science (GILD) and Regeneron (REGN) ? Cramer once proclaimed these high-fliers his “four horsemen of biotech,” but lately they’ve lost all of their traction, with Celgene down 21%, Biogen off 14%, Gilead down 9% and Regeneron off 23% so far this year.

  • [By Brian Orelli]

    Shares of Ionis Pharmaceuticals (NASDAQ:IONS) ended the day down 10.6% after an earnings reportfrom partner Biogen (NASDAQ:BIIB) started the day on a sour note. Then shares dropped even further midday after data was releasedfor IONIS-HTTRx, a treatment for Huntington’s disease. Biogen managed to end the day in the green, up 1.1%.

  • [By Stephan Byrd]

    Ladenburg Thalmann Financial Services Inc. cut its stake in shares of Biogen Inc (NASDAQ:BIIB) by 16.9% in the first quarter, HoldingsChannel.com reports. The fund owned 8,962 shares of the biotechnology company’s stock after selling 1,817 shares during the period. Ladenburg Thalmann Financial Services Inc.’s holdings in Biogen were worth $2,453,000 at the end of the most recent reporting period.

Top 5 Biotech Stocks To Watch Right Now: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Logan Wallace]

    Intact Investment Management Inc. grew its holdings in Amgen (NASDAQ:AMGN) by 2,737.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 45,400 shares of the medical research company’s stock after purchasing an additional 43,800 shares during the period. Intact Investment Management Inc.’s holdings in Amgen were worth $7,739,000 as of its most recent filing with the Securities & Exchange Commission.

  • [By Zacks]

    The FDA also approved biosimilar Erelzi in 2016. However, the launch is pending in the United States due to an ongoing litigation with Amgen (NASDAQ: AMGN).

  • [By Chris Lange]

    And Amgen Inc. (NASDAQ: AMGN) will report its most recent quarterly results late Thursday. The consensus forecast is $3.24 in EPS and $5.43 billion in revenue. Shares closed on Friday at $171.56, in a 52-week range of $152.16 to $201.23. The consensus price target is $195.14.

  • [By Stephan Byrd]

    Private Capital Group LLC boosted its stake in Amgen, Inc. (NASDAQ:AMGN) by 1,703.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,362 shares of the medical research company’s stock after purchasing an additional 2,231 shares during the period. Private Capital Group LLC’s holdings in Amgen were worth $403,000 at the end of the most recent reporting period.

Top 5 Biotech Stocks To Invest In 2019

Generally speaking, companies that reside within the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval. But consider that with the risk of failure, which could spell disaster for a stock, comes great reward as well. Some companies can see a massive upside just from winning a single midstage trial or even achieving as much as a Fast Track designation from the U.S. Food and Drug Administration (FDA).

Basically, these updates within the industry have the potential to make or break these companies.

Here 24/7 Wall St. has included a calendar of a few of the biggest companies expecting clinical trial and FDA updates in February. We have added some color, a recent trading history and a consensus analyst price target.

Its worth mentioning that these dates may be subject to change due to various internal and outside factors. Some of these changes are positive developments, and some can be disasters if a company is deeply financed.

Top 5 Biotech Stocks To Invest In 2019: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Joseph Griffin]

    BidaskClub lowered shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a strong-buy rating to a buy rating in a research report released on Monday.

  • [By Max Byerly]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($1.41) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.06. The business had revenue of $21.90 million during the quarter, compared to analysts’ expectations of $35.23 million. Alnylam Pharmaceuticals had a negative return on equity of 36.81% and a negative net margin of 565.20%. The business’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.25) earnings per share. equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.7 earnings per share for the current fiscal year.

  • [By Keith Speights]

    Speaking of competition, Ionis should have its hands full battling rivals for Tegsedi assuming the drug wins approval. Alnylam (NASDAQ:ALNY) anticipates winning FDA approval for its hATTR drug patisiran within a few weeks. Because the FDA delayed its decision on Tegsedi, Alnylam appears to be in position to reach the market first. In addition to its first-mover advantage, patisiranappears to have an edge over Tegsedi in efficacy and safety based on clinical data for the two drugs.

Top 5 Biotech Stocks To Invest In 2019: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Brian Feroldi]

    The study in questionis called ADVANCE. This phase 3 trial was designed to demonstrate noninferiority of Spectrum’s drug Rolontis when compared to Amgen’s (NASDAQ:AMGN) megablockbuster drug Neulasta in patients with early-stage breast cancer.

  • [By ]

    Booker’s report took on other companies as well. Pfizer (PFE) , Gilead Sciences (GILD) , AbbVie  (ABBV) , Amgen (AMGN) , Bristol-Myers Squibb (BMY) Eli Lilly & Co. (LLY) , and Mylan NV (MYL) are cited for everything from raising drug prices, to stock buybacks and putting shareholder interest before that of the public.

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) saw its short interest fall to 9.79 million shares from the previous level of 10.46 million. Shares were last seen at $170.00, in a 52-week trading range of $152.16 to $201.23.

  • [By Cory Renauer]

    Patient Amgen Inc.(NASDAQ:AMGN) shareholders have seen the stock quadruple in price over the past decade, plus they’ve enjoyed one of the fastest-growing dividends in biopharma. Now that the company’s launched a new migraine headache drug, investors are wondering if the former highflier can put on another memorable performance.

  • [By Joseph Griffin]

    South Dakota Investment Council lowered its stake in Amgen (NASDAQ:AMGN) by 59.4% during the 1st quarter, HoldingsChannel reports. The fund owned 77,041 shares of the medical research company’s stock after selling 112,589 shares during the quarter. South Dakota Investment Council’s holdings in Amgen were worth $13,134,000 at the end of the most recent quarter.

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) saw its short interest rise to 10.46 million shares from the previous level of 9.49 million. Shares were last seen at $171.94, in a 52-week trading range of $152.16 to $201.23.

Top 5 Biotech Stocks To Invest In 2019: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Maxx Chatsko]

    Shares of development-stage biopharma ArQule (NASDAQ:ARQL) rose nearly 17% today after the company announced two appointments to its management team in two newly created positions. Dr. Marc Schegerin will serve as senior vice president, corporate strategy, communication, and finance. Dr. Shirish Hirani will serve as senior vice president, program management and product planning.

  • [By Money Morning Staff Reports]

    But Blink and our other penny stocks to watch are unlikely to continue to lock in such spectacular gains in June. After looking at our 10 top penny stocks to watch this month, we’ll show you a small-cap stock with great profit potential in its future…

    Penny Stock Current Share Price Law Month’s Gain
    Blink Charging Co. (Nasdaq: BLNK) $7.07 439.85%
    Senes Tech Inc. (Nasdaq: SNES) $1.27 175.40%
    Vivis Inc. (Nasdaq: VVUS) $0.77 150.41%
    Adomani Inc. (Nasdaq: ADOM) $1.49 137.68%
    NF Energy Saving Co. (Nasdaq: NFEC) $2.34 134.88%
    Vaalco Energy Inc. (NYSE: EGY) $2.15 109.06%
    Heat Biologics Inc. (Nasdaq: HTBX) $2.35 99.12%
    ArQule Inc. (Nasdaq: ARQL) $4.88 90.74%
    LiqTech International Inc. (NYSE: LIQT) $0.66 85.60%
    Transenterix Inc. (NYSE: TRXC) $3.46 77.84%

    While last month’s gains are tremendous, they also illustrate the inherent dangers that come with investing in penny stocks.

  • [By Cory Renauer]

    What’s behind these dramatic gains? Read on to find out.

    Company Gain in H1 2018 Market Cap
    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) 270% $1.19 billion
    ArQule, Inc. (NASDAQ:ARQL) 235% $482 million
    Endocyte, Inc. (NASDAQ:ECYT) 222% $959 million
    Madrigal Pharmaceuticals, Inc.(NASDAQ:MDGL) 205% $3.99 billion

    Data source: YCharts.

  • [By Joseph Griffin]

    ValuEngine upgraded shares of ArQule (NASDAQ:ARQL) from a buy rating to a strong-buy rating in a research report released on Tuesday.

    Several other equities analysts have also issued reports on ARQL. Zacks Investment Research upgraded ArQule from a hold rating to a buy rating and set a $2.50 price objective for the company in a research report on Tuesday, March 20th. BidaskClub upgraded ArQule from a buy rating to a strong-buy rating in a research report on Saturday, March 24th. B. Riley set a $4.00 price objective on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Finally, Roth Capital boosted their price objective on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $5.35.

  • [By Joseph Griffin]

    Shares of ArQule, Inc. (NASDAQ:ARQL) were down 5.4% during trading on Wednesday . The company traded as low as $4.71 and last traded at $4.73. Approximately 3,358,864 shares traded hands during trading, an increase of 289% from the average daily volume of 863,008 shares. The stock had previously closed at $5.00.

Top 5 Biotech Stocks To Invest In 2019: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Lisa Levin]

    Analysts at Canaccord Genuity upgraded Biogen Inc. (NASDAQ: BIIB) from Hold to Buy.

    Biogen shares rose 2.55 percent to close at $294.40 on Tuesday.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage gain ahead of the close was Biogen Inc. (NASDAQ: BIIB) which traded up about 19% at $355.17. The stocks 52-week range is $249.17 to $370.57. Volume was over 12 million compared to the daily average volume of 1.6 million.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Wednesday was Biogen Inc. (NASDAQ: BIIB) which traded down about 6% at 297.99. The stocks 52-week range is $244.28 to $370.67. Volume was about 5 million compared to the daily average volume of roughly 1 million.

  • [By Brian Orelli]

    Drug-developer Biogen (NASDAQ:BIIB) reported a pretty strong earningsincrease in the first quarter. While revenue growth wasn’t as solid, investors appear to be giving management a pass, thanks to its explanations on why slowing first-quarter sales aren’t a sign of future trouble.

  • [By ]

    This week we get our first look at quarterly numbers from major drug and biotech giants such as AbbVie (ABBV)  , Amgen (AMGN)  , Biogen (BIIB) , Biomarin Pharmaceuticals (BMRN)  and Action Alerts PLUS holding Eli Lilly (LLY) , which all provide the market a glimpse of how the first quarter was for the industry over the next few days,” according to Real Money Pro columnist Bret Jensen.

Top 5 Biotech Stocks To Buy For 2019

Schwab Charles Investment Management Inc. lifted its stake in Anavex Life Sciences Corp (NASDAQ:AVXL) by 48.8% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 76,200 shares of the biotechnology company’s stock after purchasing an additional 25,000 shares during the period. Schwab Charles Investment Management Inc.’s holdings in Anavex Life Sciences were worth $211,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Bank of New York Mellon Corp boosted its position in shares of Anavex Life Sciences by 60.3% in the 4th quarter. Bank of New York Mellon Corp now owns 177,938 shares of the biotechnology company’s stock worth $573,000 after purchasing an additional 66,931 shares during the last quarter. Deutsche Bank AG boosted its position in shares of Anavex Life Sciences by 150.9% in the 4th quarter. Deutsche Bank AG now owns 82,967 shares of the biotechnology company’s stock worth $266,000 after purchasing an additional 49,904 shares during the last quarter. Finally, Millennium Management LLC boosted its position in shares of Anavex Life Sciences by 95.2% in the 4th quarter. Millennium Management LLC now owns 44,895 shares of the biotechnology company’s stock worth $145,000 after purchasing an additional 21,895 shares during the last quarter. Institutional investors and hedge funds own 23.00% of the company’s stock.

Top 5 Biotech Stocks To Buy For 2019: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Todd Campbell]

    Unfortunately for investors, June’s discovery wasn’t exciting enough for Sangamo partners Biogen (NASDAQ:BIIB) and Shire (NASDAQ:SHPG). In 2015, Biogen announced a delay to its beta-thalassemia and sickle-cell disease treatment program with Sangamo. And then Shire, a Sangamo collaboration partner since 2012, walked away from Sangamo’s hemophilia program.

  • [By Dan Caplinger]

    Wall Street continued its downward streak on Monday, with the Dow Jones Industrial Average falling more than 100 points. Most major benchmarks fell more modestly, with a few actually poking into positive territory on the day. Trade-sensitive stocks were among the weakest as investors focused on uncertainty related to tariff disputes between the U.S. and China. But for some other companies, bad news of a different sort was responsible for the drops in their shares. Biogen (NASDAQ:BIIB), Baytex Energy (NYSE:BTE), and Catalyst Biosciences (NASDAQ:CBIO) were among the worst performers on the day. Here’s why they did so poorly.

  • [By ]

    What should investors do with shares of Celgene (CELG) , Biogen Idec (BIIB) , Gilead Science (GILD) and Regeneron (REGN) ? Cramer once proclaimed these high-fliers his “four horsemen of biotech,” but lately they’ve lost all of their traction, with Celgene down 21%, Biogen off 14%, Gilead down 9% and Regeneron off 23% so far this year.

  • [By Logan Wallace]

    Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Tuesday, April 24th. The biotechnology company reported $6.05 earnings per share for the quarter, topping the consensus estimate of $5.93 by $0.12. The firm had revenue of $3.13 billion for the quarter, compared to analyst estimates of $3.15 billion. Biogen had a net margin of 23.54% and a return on equity of 37.64%. Biogen’s quarterly revenue was up 11.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $5.20 earnings per share. research analysts anticipate that Biogen will post 23.94 earnings per share for the current year.

  • [By Cory Renauer]

    Biotech traders get heaps of attention, but buying promising young drugmakers and holding them for the long term is a far easier way to get rich. Case in point: Spreading $10,000 evenly among shares of Biogen Inc. (NASDAQ:BIIB),Celgene Corporation (NASDAQ:CELG), andGilead Sciences Inc.(NASDAQ:GILD) around this time in 1998 would have made you a millionaire already.

  • [By Cory Renauer]

    There’s a lot for investors to like aboutAmgen Inc. (NASDAQ:AMGN) andBiogen Inc. (NASDAQ:BIIB). Both of these biotech stocks have produced tremendous returns over the past couple of decades, and the businesses they represent still generate enormous profits.

Top 5 Biotech Stocks To Buy For 2019: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Joseph Griffin]

    ValuEngine upgraded shares of ArQule (NASDAQ:ARQL) from a buy rating to a strong-buy rating in a research report released on Tuesday.

    Several other equities analysts have also issued reports on ARQL. Zacks Investment Research upgraded ArQule from a hold rating to a buy rating and set a $2.50 price objective for the company in a research report on Tuesday, March 20th. BidaskClub upgraded ArQule from a buy rating to a strong-buy rating in a research report on Saturday, March 24th. B. Riley set a $4.00 price objective on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Finally, Roth Capital boosted their price objective on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $5.35.

  • [By Joseph Griffin]

    Shares of ArQule, Inc. (NASDAQ:ARQL) were down 5.4% during trading on Wednesday . The company traded as low as $4.71 and last traded at $4.73. Approximately 3,358,864 shares traded hands during trading, an increase of 289% from the average daily volume of 863,008 shares. The stock had previously closed at $5.00.

  • [By Money Morning Staff Reports]

    But Blink and our other penny stocks to watch are unlikely to continue to lock in such spectacular gains in June. After looking at our 10 top penny stocks to watch this month, we’ll show you a small-cap stock with great profit potential in its future…

    Penny Stock Current Share Price Law Month’s Gain
    Blink Charging Co. (Nasdaq: BLNK) $7.07 439.85%
    Senes Tech Inc. (Nasdaq: SNES) $1.27 175.40%
    Vivis Inc. (Nasdaq: VVUS) $0.77 150.41%
    Adomani Inc. (Nasdaq: ADOM) $1.49 137.68%
    NF Energy Saving Co. (Nasdaq: NFEC) $2.34 134.88%
    Vaalco Energy Inc. (NYSE: EGY) $2.15 109.06%
    Heat Biologics Inc. (Nasdaq: HTBX) $2.35 99.12%
    ArQule Inc. (Nasdaq: ARQL) $4.88 90.74%
    LiqTech International Inc. (NYSE: LIQT) $0.66 85.60%
    Transenterix Inc. (NYSE: TRXC) $3.46 77.84%

    While last month’s gains are tremendous, they also illustrate the inherent dangers that come with investing in penny stocks.

  • [By Stephan Byrd]

    ArQule, Inc. (NASDAQ:ARQL) Director Ronald M. Lindsay acquired 23,900 shares of the company’s stock in a transaction on Thursday, May 10th. The stock was acquired at an average price of $2.67 per share, for a total transaction of $63,813.00. Following the purchase, the director now directly owns 43,900 shares of the company’s stock, valued at $117,213. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

  • [By Maxx Chatsko]

    Shares of development-stage biopharma ArQule (NASDAQ:ARQL) rose nearly 17% today after the company announced two appointments to its management team in two newly created positions. Dr. Marc Schegerin will serve as senior vice president, corporate strategy, communication, and finance. Dr. Shirish Hirani will serve as senior vice president, program management and product planning.

Top 5 Biotech Stocks To Buy For 2019: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Keith Speights]

    It’s not exactly David vs. Goliath. However, Bellicum Pharmaceuticals (NASDAQ:BLCM) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are definitely in different leagues right now. Both are clinical-stage biotechs, but Bellicum’s market cap is less than $350 million while Alnylam’s market cap is close to $10 billion.

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) released first-quarter results last week, but all eyes were looking forward as the company waits for a potential approval of its hereditary TTR amyloidosis (ATTR) drug, patisiran.

  • [By Keith Speights]

    I wrote three months ago that I viewed Alnylam Pharmaceuticals (NASDAQ:ALNY) stock as a pretty good pick — but with a couple of qualifications. First, I didn’t think that the biotech would generate returns in 2018 nearly as great as it did last year. Second, I thought that there were even better stocks to buy than Alnylam.

  • [By Max Byerly]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($1.41) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.06. The business had revenue of $21.90 million during the quarter, compared to analysts’ expectations of $35.23 million. Alnylam Pharmaceuticals had a negative return on equity of 36.81% and a negative net margin of 565.20%. The business’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.25) earnings per share. equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.7 earnings per share for the current fiscal year.

  • [By Sean Williams, Chuck Saletta, and Brian Feroldi]

    So, which biotech stocks should you consider buying in June? That’s a question we posed to three of our healthcare-focused investors. Interestingly enough, mid-cap biotech stocks are the clear flavor of the month. If biotech is on your radar in June, our investors suggest you consider Ionis Pharmaceuticals (NASDAQ:IONS), Spark Therapeutics (NASDAQ:ONCE), and Alnylam Pharmaceuticals (NASDAQ:ALNY).

Top 5 Biotech Stocks To Buy For 2019: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) saw its short interest fall slightly to 10.61 million shares from the previous level of 10.72 million. Shares were last seen at $184.59, in a 52-week trading range of $163.31 to $201.23.

  • [By Keith Speights]

    The big reason Humira will maintain its position at the top is the U.S. market. U.S. sales of the drug are projected to be around $12.2 billion in 2024. That’s not much lower than Humira’s 2017 U.S. sales of nearly $12.4 billion. Will Amgen’s (NASDAQ:AMGN) biosimilar Amjevita, which will go on sale in the U.S. effective Jan. 31, 2023, really make that small of a dent in Humira’s sales? Not really. The impact will be greater than the 2024 projections indicate.

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) saw its short interest fall to 9.58 million shares from the previous level of 10.61 million. Shares were last seen trading at $193.15, in a 52-week trading range of $163.31 to $201.23.

  • [By Keith Speights]

    Amgen (NASDAQ:AMGN) has been the hands-down winner over Celgene (NASDAQ:CELG) in terms of stock performance over the last year. It’s the same story for revenue generated. Celgene beat Amgen in earnings, but only because of a technicality: Amgen incurred a big one-time tax hit in 2017.

  • [By Brian Feroldi]

    The study in questionis called ADVANCE. This phase 3 trial was designed to demonstrate noninferiority of Spectrum’s drug Rolontis when compared to Amgen’s (NASDAQ:AMGN) megablockbuster drug Neulasta in patients with early-stage breast cancer.

  • [By Max Byerly]

    Amgen (NASDAQ: AMGN) and aTyr Pharma (NASDAQ:LIFE) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership.

Hot Biotech Stocks To Buy For 2019

Shares of Inovio Pharmaceuticals(INO) are climbing today after the biotech company announced that it would begin testing a Zika vaccine in Puerto Rico. Maxim’sJason McCarthy andJason Kolbert have the details:

CREDIT: Alex Wild Published Credit: Alex Wild Alex Wild

Inovio announced the initiation of a small clinical study (N=160) of its Zika vaccine, GLS-5700 (being developed with GeneOne Life Sciences), in Puerto Rico. It is estimated by the CDC that the Zika virus could infect more than 25% of the population of Puerto Rico by YE16.The study will evaluate safety, immunogenicity and early signs of efficacy in preventing Zika infection. Data are expected in 2017, and if positive, Inovio will discuss with regulators the best path forward.

In addition, the phase I study of GLS-5700 (N=40) in the U.S. and Canada, which is the first in-human Zika vaccine study, is now fully enrolled. Data evaluating safety and immunogenicity are expected by YE16.

Hot Biotech Stocks To Buy For 2019: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Brian Orelli]

    The delay in an FDA decision for Tegsedi puts it behind competitor Alnylam Pharmaceuticals (NASDAQ:ALNY), which expects to hear from the FDA by Aug. 11 for its hATTR drug patisiran. But Sarah Boyce, the president at Akcea Therapeutics, doesn’t think a few months will really matter: “We don’t really feel that’s going to have any impact and the drugs will be close enough together from a launch perspective. So not really [going] to make any adjustments, and we’re very well prepared to be ready to launch following approval.”

  • [By Logan Wallace]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Although Alnylam has a broad and promising pipeline, we note that most candidates are in mid stages of development. These candidates still have a long way to go before hitting the market. The company relies highly on collaborators for funding. Any development/regulatory setback would be a negative for the company.  However, Alnylam reported positive data from the ATLAS study in the first quarter which led to regulatory filings for its late-stage pipeline candidate patisiran and the FDA set an action date of Aug 11, 2018. The company along with its partners Sanofi and The Medicines Company, restarted fitusiran's ATLAS phase III study and advanced inclisiran in the ORION-9, -10, and -11 phase III studies, respectively, with results expected for both programs in 2019. Alnylam expects to achieve the profile of three marketed products by the end of 2020.”

  • [By Joseph Griffin]

    BidaskClub lowered shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a strong-buy rating to a buy rating in a research report released on Monday.

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) released first-quarter results last week, but all eyes were looking forward as the company waits for a potential approval of its hereditary TTR amyloidosis (ATTR) drug, patisiran.

Hot Biotech Stocks To Buy For 2019: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) saw its short interest fall to 9.58 million shares from the previous level of 10.61 million. Shares were last seen trading at $193.15, in a 52-week trading range of $163.31 to $201.23.

  • [By ]

    Booker’s report took on other companies as well. Pfizer (PFE) , Gilead Sciences (GILD) , AbbVie  (ABBV) , Amgen (AMGN) , Bristol-Myers Squibb (BMY) Eli Lilly & Co. (LLY) , and Mylan NV (MYL) are cited for everything from raising drug prices, to stock buybacks and putting shareholder interest before that of the public.

  • [By Cory Renauer]

    There’s a lot for investors to like aboutAmgen Inc. (NASDAQ:AMGN) andBiogen Inc. (NASDAQ:BIIB). Both of these biotech stocks have produced tremendous returns over the past couple of decades, and the businesses they represent still generate enormous profits.

Hot Biotech Stocks To Buy For 2019: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Shannon Jones]

    In this week’s episode of Industry Focus: Healthcare, host Michael Douglass and Motley Fool contributor Shannon Jones look at what went wrong with Incyte’s Epacadostat, where the company can go from here, and what this unfortunately means for the immuno-oncology sector on the whole. Then, in more pleasant news, the hosts dive into Novartis’ (NYSE:NVS) newest acquisition of gene therapy company AveXis. Find out what this means for Novartis, why Biogen (NASDAQ:BIIB)might be getting the stink eye from their investors right about now, whether or not Novartis overpaid to tuck this company under their belt, and more.

  • [By Todd Campbell]

    The acquisition of AveXis resulted in an $80 million milestone payment to Regenxbio in Q1 and an additional $100 million payment in June. If AVXS-101 wins an OK, Regenxbio will receive sales royalties in the mid single to low double digits, which could add up to hundreds of millions of dollars annually. For perspective,Biogen’s (NASDAQ:BIIB) Spinraza became the only FDA-approved treatmentfor SMA in late 2016, and its sales are already tracking at an annualized pace of over $1.2 billion, even though only 40% of patients see an improvement on it.

  • [By Chris Lange]

    Biogen Inc. (NASDAQ: BIIB) is expected to report its first-quarter results early on Tuesday. The consensus forecast calls for $5.92 in earnings per share (EPS) and revenue of $3.15 billion. Shares of Biogen ended last week at $263.02. The consensus analyst price target is all the way up at $371.97. The 52-week trading range is $244.28 to $370.57.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close was Biogen Inc. (NASDAQ: BIIB) which traded down over 5% at $288.75. The stocks 52-week range is $249.17 to $370.57. Volume was 3.2 million compared to the daily average volume of 1.7 million.

  • [By Jim Crumly]

    As for individual stocks, Biogen (NASDAQ:BIIB) made headlines with positive results from a trial of an Alzheimer’s drug, and PriceSmart (NASDAQ:PSMT) fell after reporting earnings.

Hot Biotech Stocks To Buy For 2019: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Cory Renauer]

    What’s behind these dramatic gains? Read on to find out.

    Company Gain in H1 2018 Market Cap
    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) 270% $1.19 billion
    ArQule, Inc. (NASDAQ:ARQL) 235% $482 million
    Endocyte, Inc. (NASDAQ:ECYT) 222% $959 million
    Madrigal Pharmaceuticals, Inc.(NASDAQ:MDGL) 205% $3.99 billion

    Data source: YCharts.

  • [By Logan Wallace]

    BidaskClub upgraded shares of ArQule (NASDAQ:ARQL) from a hold rating to a buy rating in a report released on Saturday.

    A number of other research firms have also issued reports on ARQL. Roth Capital upped their price target on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Zacks Investment Research lowered ArQule from a buy rating to a hold rating in a research report on Wednesday, April 4th. ValuEngine upgraded ArQule from a hold rating to a buy rating in a research report on Wednesday, May 2nd. Finally, B. Riley set a $4.00 price target on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Seven analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and an average target price of $4.69.

  • [By Joseph Griffin]

    ValuEngine upgraded shares of ArQule (NASDAQ:ARQL) from a buy rating to a strong-buy rating in a research report released on Tuesday.

    Several other equities analysts have also issued reports on ARQL. Zacks Investment Research upgraded ArQule from a hold rating to a buy rating and set a $2.50 price objective for the company in a research report on Tuesday, March 20th. BidaskClub upgraded ArQule from a buy rating to a strong-buy rating in a research report on Saturday, March 24th. B. Riley set a $4.00 price objective on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Finally, Roth Capital boosted their price objective on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $5.35.

  • [By Lisa Levin] Gainers
    Melinta Therapeutics, Inc. (NASDAQ: MLNT) shares surged 20.6 percent to $6.39. WBB Securities upgraded Melinta Therapeutics from Hold to Speculative Buy.
    Shoe Carnival, Inc. (NASDAQ: SCVL) shares climbed 17.2 percent to $30.87 after the company reported upbeat quarterly earnings.
    Acorn International, Inc. (NYSE: ATV) shares rose 15.2 percent to $28.804 after the company declared a special one-time cash dividend of $14.97 per ADS.
    Foot Locker, Inc. (NYSE: FL) gained 15 percent to $53.35 after the company reported better-than-expected results for its first quarter.
    Sears Hometown and Outlet Stores, Inc. (NASDAQ: SHOS) surged 14.2 percent to $2.625.
    ArQule, Inc. (NASDAQ: ARQL) rose 13 percent to $5.12 after gaining 4.86 percent on Thursday.
    Quality Systems, Inc. (NASDAQ: QSII) gained 12.8 percent to $16.97 after the company posted better-than-expected FQ4 results.
    Loma Negra Compañía Industrial Argentina Sociedad Anónima (NYSE: LOMA) shares rose 12 percent to $12.94.
    ArQule, Inc. (NASDAQ: ARQL) shares rose 12 percent to $5.07.
    Mirati Therapeutics, Inc. (NASDAQ: MRTX) climbed 11.4 percent to $43.50.
    Zai Lab Limited (NASDAQ: ZLAB) gained 11.3 percent to $24.7000.
    Zymeworks Inc. (NASDAQ: ZYME) rose 9.7 percent to $19.64.
    Park City Group, Inc. (NASDAQ: PCYG) climbed 9 percent to $7.90.
    Roku, Inc. (NASDAQ: ROKU) gained 7.9 percent to $38.82 after Citron reversed previously bearish position on the stock.
    Sears Holdings Corporation (NASDAQ: SHLD) shares jumped 7.3 percent to $3.55.
    Deckers Outdoor Corp (NYSE: DECK) rose 3.5 percent to $107.27 after reporting better-than-expected results for its fiscal fourth quarter.

    Check out these big penny stock gainers and losers

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on ArQule (ARQL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Heal Care Stocks To Own Right Now

Some might think investors in their 60s should steer clear of stocks. And that’s not entirely correct.

Sure, shifting some of your portfolio to less volatile investing alternatives like bonds makes sense. However, stocks should still be an important component of investment accounts for individuals in this age group. The big question, though, is: Which stocks to buy?

I think Alphabet (NASDAQ:GOOG) (NASDAQ:GOOGL), Iron Mountain (NYSE:IRM), and Pfizer (NYSE:PFE) are great picks for investors in their 60s. Here’s what makes these three stocks stand out.

Alphabet
You might be surprised for Google parent Alphabet to make the list since the stock doesn’t pay a dividend. But while it’s great to have solid dividend stocks in your portfolio (and we’ll get to two of them shortly), stocks of companies with strong moats and excellent growth prospects should be included as well. Alphabet checks off both of those boxes in a big way.

Top 10 Heal Care Stocks To Own Right Now: Akamai Technologies, Inc.(AKAM)

Advisors’ Opinion:

  • [By ]

    Meanwhile, Akamai’s (AKAM) CEO Tom Leighton didn’t shut the door to a potential sale of the company in an interview with me. Recent speculation on Wall Street is that Akamai would be an ideal fit for IBM (IBM) . 

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Thursday was Akamai Technologies, Inc. (NASDAQ: AKAM) which rose about 7% to $74.89. The stocks 52-week range is $44.65 to $75.00. Volume was roughly 4 million compared to the daily average volume of 2.3 million.

  • [By ]

    There could be a for sale sign planted in the ground at tech pioneer Akamai (AKAM) .

    “We’re a public company and our board, which is very professional and diligent, is always going to do the right thing for shareholders,” Akamai CEO Tom Leighton told TheStreet when asked if the company he co-founded in 1998 was for sale. While Leighton left the door open on a possible sale, he added that Akamai has strong prospects as a stand-alone company as well.

  • [By Joseph Griffin]

    Limelight Networks (NASDAQ: LLNW) and Akamai Technologies (NASDAQ:AKAM) are both computer and technology companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Top 10 Heal Care Stocks To Own Right Now: Retail Properties of America, Inc.(RPAI)

Advisors’ Opinion:

  • [By Lee Jackson]

    Retail Properties of America Inc. (NYSE: RPAI) investors receive a 5.7% yield. The stock was last seen trading at $11.45 a share. The 52-week range is $10.94 to $14.70, and the consensus price target is $15.44.

  • [By Shane Hupp]

    Press coverage about Retail Properties of America (NYSE:RPAI) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Retail Properties of America earned a news impact score of 0.19 on Accern’s scale. Accern also assigned press coverage about the real estate investment trust an impact score of 48.1880076437209 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Retail Properties of America (RPAI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Heal Care Stocks To Own Right Now: Patriot Transportation Holding, Inc.(PATI)

Advisors’ Opinion:

  • [By Shane Hupp]

    Patriot Transportation Holding Inc (NASDAQ:PATI) VP John D. Milton, Jr. sold 5,601 shares of the business’s stock in a transaction that occurred on Thursday, June 14th. The shares were sold at an average price of $22.51, for a total value of $126,078.51. Following the sale, the vice president now owns 402 shares in the company, valued at $9,049.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Top 10 Heal Care Stocks To Own Right Now: Eaton Vance Enhanced Equity Income Fund II(EOS)

Advisors’ Opinion:

  • [By Shane Hupp]

    EOS (CURRENCY:EOS) traded up 9.3% against the US dollar during the 1 day period ending at 20:00 PM E.T. on July 2nd. During the last week, EOS has traded up 8.5% against the US dollar. One EOS token can now be purchased for $8.89 or 0.00135160 BTC on exchanges including Zebpay, CoinEx Market, ChaoEX and Tidex. EOS has a market cap of $7.96 billion and $1.02 billion worth of EOS was traded on exchanges in the last day.

  • [By Stephan Byrd]

    EOS (CURRENCY:EOS) traded 4.1% higher against the US dollar during the 24 hour period ending at 14:00 PM E.T. on June 27th. EOS has a total market capitalization of $7.24 billion and $772.07 million worth of EOS was traded on exchanges in the last 24 hours. Over the last week, EOS has traded down 22.9% against the US dollar. One EOS token can currently be purchased for approximately $8.08 or 0.00131687 BTC on major cryptocurrency exchanges including Kuna, Bibox, Cryptopia and CoinExchange.

  • [By Joseph Griffin]

    EOS (CURRENCY:EOS) traded 0.7% higher against the U.S. dollar during the 1 day period ending at 16:00 PM ET on July 4th. In the last seven days, EOS has traded 13.1% higher against the U.S. dollar. One EOS token can now be purchased for approximately $9.05 or 0.00135304 BTC on major cryptocurrency exchanges including DragonEX, ChaoEX, Hotbit and HitBTC. EOS has a market cap of $8.11 billion and approximately $912.71 million worth of EOS was traded on exchanges in the last 24 hours.

Top 10 Heal Care Stocks To Own Right Now: TripAdvisor, Inc.(TRIP)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Tripadvisor Inc Common Stock (NASDAQ: TRIP) and Match Group (NASDAQ:MTCH) are both retail/wholesale companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability.

  • [By Demitrios Kalogeropoulos]

    There are many reasons an investor might be attracted to TripAdvisor (NASDAQ:TRIP) stock. It boasts an enviable position in the online hotel booking space, after all, and the travel specialist is cultivating new business lines that might soon become significant revenue streams in their own rights.

  • [By Dan Caplinger]

    For a travel website to prosper, it should ideally see growing business in every aspect of travel. Between hotels, airfare, rental cars, and attractions, travelers spend a lot of money, and investors look to TripAdvisor (NASDAQ:TRIP) to claim its fair share of that growing pie. Yet in large part due to rising competitive pressures, TripAdvisor has had trouble finding the growth that shareholders expect, and much of what’s holding it back comes from a part of the travel business that you’d think would be doing better for the company.

  • [By Lisa Levin] Gainers
    Amedica Corporation (NASDAQ: AMDA) rose 31.3 percent to $4.11 in pre-market trading after climbing 181.98 percent on Tuesday.
    ZAGG Inc (NASDAQ: ZAGG) rose 18.7 percent to $13.65 in pre-market trading after the company posted better-than-expected Q1 earnings.
    TripAdvisor, Inc. (NASDAQ: TRIP) rose 18.6 percent to $46.00 in pre-market trading after the company reported stronger-than-expected results for its first quarter on Tuesday.
    TransEnterix, Inc. (NYSE: TRXC) shares rose 15 percent to $2.08 in pre-market trading after reporting Q4 results.
    Axon Enterprise, Inc. (NASDAQ: AAXN) rose 9.8 percent to $49.00 in pre-market trading following a big Q1 beat. The company raised its fiscal 2018 sales growth guidance from 16-18 percent to 18-20 percent.
    Centennial Resource Development, Inc. (NASDAQ: CDEV) shares rose 8.1 percent to $21.06 in pre-market trading following Q1 results.
    OPKO Health, Inc. (NASDAQ: OPK) shares rose 6.8 percent to $3.44 in pre-market trading following Q1 beat.
    Tel-Instrument Electronics Corp. (NYSE: TIK) rose 6.7 percent to $3.20 in pre-market trading after surging 25.37 percent on Tuesday.
    KBS Fashion Group Limited (NASDAQ: KBSF) rose 6.4 percent to $5.84 in pre-market trading after jumping 9.36 percent on Tuesday.
    Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) rose 6.6 percent to $8.26 in pre-market trading after reporting Q2 earnings.
    New Relic, Inc. (NYSE: NEWR) rose 6.3 percent to $82.00 in pre-market trading following Q4 results.
    Match Group, Inc. (NASDAQ: MTCH) rose 5.8 percent to $38.43 in pre-market trading after reporting upbeat Q1 earnings.
    Prestige Brands Holdings, Inc. (NYSE: PBH) rose 5.2 percent to $30.62 in pre-market trading.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By Steve Symington]

    Shares ofTripAdvisor (NASDAQ:TRIP) were down 12.9% as of 2:50 p.m. EDT Thursday after the online travel site announced mixed second-quarter 2018 results. TripAdvisor’s quarterly revenue grew 2% year over year, to $433 million, and translated to adjusted net income of $58 million, or $0.41 per share, up from $0.38 per share in the same year-ago period.

Top 10 Heal Care Stocks To Own Right Now: Chuy's Holdings, Inc.(CHUY)

Advisors’ Opinion:

  • [By Logan Wallace]

    News headlines about Chuy’s (NASDAQ:CHUY) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Chuy’s earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave headlines about the restaurant operator an impact score of 46.3414123476192 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

  • [By Max Byerly]

    Chuy’s (NASDAQ:CHUY) CEO Steven J. Hislop sold 3,690 shares of the company’s stock in a transaction dated Friday, May 4th. The stock was sold at an average price of $30.00, for a total transaction of $110,700.00. Following the completion of the transaction, the chief executive officer now owns 132,460 shares in the company, valued at approximately $3,973,800. The sale was disclosed in a legal filing with the SEC, which is available through this link.

  • [By Joseph Griffin]

    Chuy’s (NASDAQ:CHUY) had its price target hoisted by BMO Capital Markets from $27.00 to $28.00 in a report published on Wednesday, Marketbeat.com reports. The firm currently has a hold rating on the restaurant operator’s stock.

  • [By Shane Hupp]

    Arcos Dorados (NYSE: ARCO) and Chuy’s (NASDAQ:CHUY) are both small-cap retail/wholesale companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

  • [By Motley Fool Staff]

    Chuy’s Holdings (NASDAQ:CHUY) Q1 2018 Earnings Conference CallMay. 8, 2018 4:30 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Dustin Parrett]

    Here are the top restaurant stocks we’ve found, with one-year price targets showing gains as high as 74%…

    Restaurant Stocks to Buy, No. 1: Chuy’s Holdings Inc. (Nasdaq: CHUY)

    Chuy’s Holdings Inc. (Nasdaq: CHUY) is a Texas-based chain of casual Tex-Mex restaurants.

Top 10 Heal Care Stocks To Own Right Now: Performant Financial Corporation(PFMT)

Advisors’ Opinion:

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Check-Cap Ltd. (NASDAQ: CHEK) shares dipped 47.8 percent to $4.60. Check-Cap priced its upsized underwritten offering of public units at $5.50 per unit.
    VivoPower International PLC (NASDAQ: VVPR) shares fell 41.5 percent to $2.57.
    Universal Electronics Inc. (NASDAQ: UEIC) dropped 35.1 percent to $29.50 after the company posted downbeat quarterly results.
    Euro Tech Holdings Company Limited (NASDAQ: CLWT) dropped 34.8 percent to $3.75 after climbing 155.56 percent on Thursday.
    Integrated Media Technology Limited (NASDAQ: IMTE) fell 25.2 percent to $24.01 after surging 46.29 percent on Thursday.
    Fluor Corporation (NYSE: FLR) dropped 22.5 percent to $45.73 after the company reported downbeat earnings for its first quarter and lowered its profit outlook for the year.
    AMN Healthcare Services, Inc (NYSE: AMN) shares fell 19.6 percent to $52.075 following Q1 earnings.
    Adverum Biotechnologies, Inc. (NASDAQ: ADVM) shares declined 18.1 percent to $5.20. Adverum Biotech disclosed that its CEO Amber Salzman is stepping down.
    Newater Technology, Inc. (NASDAQ: NEWA) dropped 17.2 percent to $12.83.
    Basic Energy Services, Inc. (NYSE: BAS) fell 17.2 percent to $13.65 following Q1 results.
    Xperi Corporation (NASDAQ: XPER) declined 15.8 percent to $19.40 after announcing Q1 results.
    Sharing Economy International Inc. (NASDAQ: SEII) shares fell 15.1 percent to $3.649 after climbing 22.16 percent on Thursday.
    Performant Financial Corporation (NASDAQ: PFMT) dropped 14.2 percent to $2.65.
    Gogo Inc. (NASDAQ: GOGO) shares fell 13.2 percent to $8.32 after the company reported Q1 results and disclosed that it is withdrawing its FY18 outlook for adjusted EBITDA, airborne cash capex, airborne equipment inventory purchases and free cash flow.
    Technical Communications Corporation (NASDAQ: TCCO) dropped 12.2 percent to $5.05.
    Web.com Group, Inc. (NASDAQ: WEB) fell 9.7 percent

  • [By Lisa Levin]

    Shares of Performant Financial Corporation (NASDAQ: PFMT) were down 29 percent to $2.20. Performant Financial is expected to release Q1 earnings on May 8.

  • [By Stephan Byrd]

    Performant Financial (NASDAQ: PFMT) and Donnelley Financial Solns (NYSE:DFIN) are both small-cap business services companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk.

  • [By Ethan Ryder]

    SEA (NYSE: SE) and Performant Financial (NASDAQ:PFMT) are both finance companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Top 10 Heal Care Stocks To Own Right Now: LiqTech International, Inc.(LIQT)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares climbed 70.3 percent to $5.45 after reporting 2017 year-end results.
    MEDIGUS Ltd/S ADR (NASDAQ: MDGS) surged 39.8 percent to $1.58 in reaction to its Monday announcement of a distribution agreement. The medical device company said it reached an agreement to distribute its minimally invasive medical devices in Turkey, Azerbaijan and Georgia.
    Arcadia Biosciences, Inc. (NASDAQ: RKDA) gained 25.6 percent to $11.50. Arcadia Biosciences reported that Albert D. Bolles, Ph.D. has joined its board of directors.
    Aytu Bioscience Inc (NASDAQ: AYTU) shares jumped 21.8 percent to $0.4798 after the company late Monday reported lighter-than-expected Q1 loss.
    Hollysys Automation Technologies Ltd. (NASDAQ: HOLI) shares gained 21.1 percent to $26.77 following Q3 results.
    Pfenex Inc. (NYSE: PFNX) rose 16.8 percent to $7.1271 after the company announced the positive top-line PF708 study results in Osteoporosis patients that showed no imbalances in severity or incidence of adverse events.
    MEI Pharma, Inc. (NASDAQ: MEIP) rose 13.8 percent to $2.88.
    Red Violet, Inc. (NASDAQ: RDVT) jumped 13.1 percent to $6.41 after reporting Q1 results.
    SORL Auto Parts, Inc. (NASDAQ: SORL) shares gained 12 percent to $5.87 after reporting upbeat Q1 results.
    Bovie Medical Corporation (NYSE: BVX) gained 8.4 percent to $3.96 after reporting a first-quarter sales beat.
    Rosehill Resources Inc. (NASDAQ: ROSE) surged 8.4 percent to $7.90 after announcing Q1 results.
    LiqTech International, Inc. (NASDAQ: LIQT) rose 8.1 percent to $0.5171 following Q1 results.
    ProPhase Labs, Inc. (NASDAQ: PRPH) rose 7.7 percent to $5.6103 following Q1 results.
    Nine Energy Service, Inc. (NYSE: NINE) shares climbed 7.4 percent to $35.90.
    Xenon Pharmaceuticals Inc. (NASDAQ: XENE) rose 6.7 percent to $6.40 after the company presented XEN901 Phase 1 clinical update and XEN1101 TMS pharmacodynamic Phase 1 data.
    MYnd
  • [By Lisa Levin] Gainers
    Red Violet, Inc. (NASDAQ: RDVT) rose 75.31 percent to close at $9.94 after reporting Q1 results.
    Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares jumped 40.62 percent to close at $4.50 on Tuesday after reporting 2017 year-end results.
    MEI Pharma, Inc. (NASDAQ: MEIP) gained 34.39 percent to close at $3.40.
    MEDIGUS Ltd/S ADR (NASDAQ: MDGS) gained 32.74 percent to close at $1.50 in reaction to its Monday announcement of a distribution agreement. The medical device company said it reached an agreement to distribute its minimally invasive medical devices in Turkey, Azerbaijan and Georgia.
    Pfenex Inc. (NYSE: PFNX) surged 31.15 percent to close at $8.00 after the company announced the positive top-line PF708 study results in Osteoporosis patients that showed no imbalances in severity or incidence of adverse events.
    Arcadia Biosciences, Inc. (NASDAQ: RKDA) rose 21.07 percent to close at $11.09. Arcadia Biosciences reported that Albert D. Bolles, Ph.D. has joined its board of directors.
    Genprex, Inc. (NASDAQ: GNPX) rose 20.23 percent to close at $10.58.
    Turtle Beach Corporation (NASDAQ: HEAR) shares gained 17.62 percent to close at $17.82.
    Aptevo Therapeutics Inc. (NASDAQ: APVO) rose 17.1 percent to close at $5.82.
    Phoenix New Media Limited (NYSE: FENG) shares jumped 16.23 percent to close at $4.87 following Q1 earnings.
    Stein Mart, Inc. (NASDAQ: SMRT) rose 16.04 percent to close at $3.69.
    PPDAI Group Inc. (NASDAQ: PPDF) climbed 15.99 percent to close at $7.98 following Q1 results.
    Tyme Technologies, Inc. (NASDAQ: TYME) rose 15.93 percent to close at $3.42.
    LiqTech International, Inc. (NASDAQ: LIQT) gained 15.59 percent to close at $0.5532 following Q1 results.
    Sophiris Bio, Inc. (NASDAQ: SPHS) gained 13.92 percent to close at $3.52 on Tuesday following Q1 results.
    Euroseas Ltd. (NASDAQ: ESEA) jumped 13.4 percent to close at $2.37.
    Iteris, Inc. (NASDAQ: ITI) shares surged 13.05 percent to close
  • [By Money Morning Staff Reports]

    But Blink and our other penny stocks to watch are unlikely to continue to lock in such spectacular gains in June. After looking at our 10 top penny stocks to watch this month, we’ll show you a small-cap stock with great profit potential in its future…

    Penny Stock Current Share Price Law Month’s Gain
    Blink Charging Co. (Nasdaq: BLNK) $7.07 439.85%
    Senes Tech Inc. (Nasdaq: SNES) $1.27 175.40%
    Vivis Inc. (Nasdaq: VVUS) $0.77 150.41%
    Adomani Inc. (Nasdaq: ADOM) $1.49 137.68%
    NF Energy Saving Co. (Nasdaq: NFEC) $2.34 134.88%
    Vaalco Energy Inc. (NYSE: EGY) $2.15 109.06%
    Heat Biologics Inc. (Nasdaq: HTBX) $2.35 99.12%
    ArQule Inc. (Nasdaq: ARQL) $4.88 90.74%
    LiqTech International Inc. (NYSE: LIQT) $0.66 85.60%
    Transenterix Inc. (NYSE: TRXC) $3.46 77.84%

    While last month’s gains are tremendous, they also illustrate the inherent dangers that come with investing in penny stocks.

  • [By Shane Hupp]

    LiqTech International Inc (NYSEAMERICAN:LIQT) saw a significant decline in short interest in the month of June. As of June 15th, there was short interest totalling 320,188 shares, a decline of 9.3% from the May 31st total of 352,974 shares. Currently, 0.6% of the company’s shares are short sold. Based on an average daily volume of 364,702 shares, the short-interest ratio is presently 0.9 days.

Top 10 Heal Care Stocks To Own Right Now: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Logan Wallace]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Although Alnylam has a broad and promising pipeline, we note that most candidates are in mid stages of development. These candidates still have a long way to go before hitting the market. The company relies highly on collaborators for funding. Any development/regulatory setback would be a negative for the company.  However, Alnylam reported positive data from the ATLAS study in the first quarter which led to regulatory filings for its late-stage pipeline candidate patisiran and the FDA set an action date of Aug 11, 2018. The company along with its partners Sanofi and The Medicines Company, restarted fitusiran's ATLAS phase III study and advanced inclisiran in the ORION-9, -10, and -11 phase III studies, respectively, with results expected for both programs in 2019. Alnylam expects to achieve the profile of three marketed products by the end of 2020.”

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) released first-quarter results last week, but all eyes were looking forward as the company waits for a potential approval of its hereditary TTR amyloidosis (ATTR) drug, patisiran.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Keith Speights]

    It’s not exactly David vs. Goliath. However, Bellicum Pharmaceuticals (NASDAQ:BLCM) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are definitely in different leagues right now. Both are clinical-stage biotechs, but Bellicum’s market cap is less than $350 million while Alnylam’s market cap is close to $10 billion.

Top 10 Heal Care Stocks To Own Right Now: Prudential Public Limited Company(PUK)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Here are some of the news headlines that may have effected Accern’s rankings:

    Get Prudential alerts:

    Zacks Investment Research Lowers Prudential (PUK) to Hold (americanbankingnews.com) Financial wellness program popularity rises among employers, up 63 percentage points in two years (markets.financialcontent.com) FY2018 EPS Estimates for Prudential (PUK) Reduced by Jefferies Group (americanbankingnews.com) Jefferies Group Weighs in on Prudential’s FY2020 Earnings (PUK) (americanbankingnews.com) ValuEngine Downgrades Prudential (PUK) to Hold (americanbankingnews.com)

    Shares of PUK stock traded down $0.02 during trading on Tuesday, hitting $51.56. 141,455 shares of the stock traded hands, compared to its average volume of 198,097. The firm has a market cap of $66.49 billion, a PE ratio of 13.79, a PEG ratio of 1.34 and a beta of 1.55. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.03 and a current ratio of 0.03. Prudential has a 52-week low of $44.49 and a 52-week high of $55.36.

  • [By Ethan Ryder]

    Prudential (NYSE: PUK) and Reinsurance Group of America (NYSE:RGA) are both finance companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

  • [By Ethan Ryder]

    ValuEngine lowered shares of Prudential (NYSE:PUK) from a buy rating to a hold rating in a research note issued to investors on Wednesday morning.

    Several other analysts have also recently issued reports on the stock. Zacks Investment Research upgraded shares of Prudential from a hold rating to a buy rating and set a $57.00 target price on the stock in a research note on Tuesday, March 27th. Berenberg Bank cut shares of Prudential from a hold rating to a sell rating in a research note on Thursday, March 29th. Finally, Citigroup cut shares of Prudential from a buy rating to a neutral rating in a research note on Wednesday, April 25th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. The stock currently has an average rating of Hold and an average price target of $57.00.